Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various n...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-02, Vol.21 (3), p.1054
Main Authors: Kruse, Aaron, Abdel-Azim, Nour, Kim, Hye Na, Ruan, Yongsheng, Phan, Valerie, Ogana, Heather, Wang, William, Lee, Rachel, Gang, Eun Ji, Khazal, Sajad, Kim, Yong-Mi
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antigens
b-cell acute lymphoblastic leukemia
Bone marrow
Cardiomyopathy
Chemotherapy
Diagnostic systems
Flow Cytometry
Gene expression
High-Throughput Nucleotide Sequencing
Humans
Kinases
Leukemia
Lymphatic leukemia
Lymphocytes
Medical prognosis
Minimal residual disease
Mutation
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - genetics
Neoplasm, Residual - diagnosis
Neoplasm, Residual - genetics
Neoplastic Cells, Circulating - pathology
Neuropsychology
Next-generation sequencing
Patients
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Radiation therapy
Reverse transcription
Review
Sensitivity
Stem cells
t-cell acute lymphoblastic leukemia
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21031054